Correction to: D.J. Jackson, M.E. Wechsler, G. Brusselle, R. Buhl. Targeting the IL-5 pathway in eosinophilic asthma: A comparison of anti-IL-5 versus anti-IL-5 receptor agents. Allergy 2024; 79: 2943-2952. https://doi.org/10.1111/all.16346

IF 12 1区医学 Q1 ALLERGY Allergy Pub Date : 2025-04-03 DOI:10.1111/all.16541

{"title":"Correction to: D.J. Jackson, M.E. Wechsler, G. Brusselle, R. Buhl. Targeting the IL-5 pathway in eosinophilic asthma: A comparison of anti-IL-5 versus anti-IL-5 receptor agents. Allergy 2024; 79: 2943-2952. https://doi.org/10.1111/all.16346","authors":"","doi":"10.1111/all.16541","DOIUrl":null,"url":null,"abstract":"The below sentence in Paragraph 2 of the Summary section on Page 2949 of the article is factually incorrect and supported by an outdated reference. We would therefore like to issue a corrigendum to correct this sentence, as outlined below:Original sentence: However, costs may differ between different countries, where, for example in Spain, mepolizumab can be self-administered and is a more cost-effective option than benralizumab or reslizumab.62New sentence: From a cost-effectiveness 5-year simulation model conducted in Spain, benralizumab was more effective (benralizumab: 2.87 exacerbations, 52.21 QALYs; mepolizumab: 4.70 exacerbations, 51.39 QALYs; dupilumab: 5.11 exacerbations, 51.30 QALYs) and less costly (total cost per patient, benralizumab: €56,093.57; mepolizumab: €59,280.45; dupilumab: €62,991.76) compared with mepolizumab and dupilumab for patients with uncontrolled severe eosinophilic asthma.62New reference (Ref 62): Mareque, M, Climente, M, Martinez-Moragon, E, et al. Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain. Journal of Asthma. 2022;60(6): 1210–1220. https://doi.org/10.1080/02770903.2022.2139718We apologize for this error.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"80 5","pages":""},"PeriodicalIF":12.0000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.16541","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/all.16541","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

The below sentence in Paragraph 2 of the Summary section on Page 2949 of the article is factually incorrect and supported by an outdated reference. We would therefore like to issue a corrigendum to correct this sentence, as outlined below:

Original sentence: However, costs may differ between different countries, where, for example in Spain, mepolizumab can be self-administered and is a more cost-effective option than benralizumab or reslizumab.⁶²

New sentence: From a cost-effectiveness 5-year simulation model conducted in Spain, benralizumab was more effective (benralizumab: 2.87 exacerbations, 52.21 QALYs; mepolizumab: 4.70 exacerbations, 51.39 QALYs; dupilumab: 5.11 exacerbations, 51.30 QALYs) and less costly (total cost per patient, benralizumab: €56,093.57; mepolizumab: €59,280.45; dupilumab: €62,991.76) compared with mepolizumab and dupilumab for patients with uncontrolled severe eosinophilic asthma.⁶²

New reference (Ref 62): Mareque, M, Climente, M, Martinez-Moragon, E, et al. Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain. Journal of Asthma. 2022;60(6): 1210–1220. https://doi.org/10.1080/02770903.2022.2139718

We apologize for this error.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

更正：D.J. Jackson， M.E.威克斯勒，G. Brusselle， R. Buhl。在嗜酸性粒细胞哮喘中靶向IL-5通路：抗IL-5与抗IL-5受体药物的比较过敏2024;1 - 10。https://doi.org/10.1111/all.16346。

文章第2949页总结部分第二段的下面这句话实际上是不正确的，并且有一个过时的参考文献支持。原句：然而，不同国家的成本可能不同，例如在西班牙，mepolizumab可以自行给药，是比benralizumab或reslizumab更具成本效益的选择。62新句：从西班牙进行的5年成本-效果模拟模型来看，贝纳利珠单抗更有效(贝纳利珠单抗：2.87次加重，52.21次qaly；mepolizumab: 4.70次加重，51.39次qaly；dupilumab: 5.11次恶化，51.30个QALYs)和更低的成本(每位患者的总成本，benralizumab: 56,093.57欧元；mepolizumab:€59280 .45;Dupilumab: 62,991.76欧元)，与mepolizumab和Dupilumab相比，用于治疗未控制的严重嗜酸性粒细胞哮喘患者。[2]陈晓明，陈晓明，陈晓明，等。benralizumab与mepolizumab和dupilumab在西班牙严重不受控制的嗜酸性粒细胞哮喘患者中的成本效益中华哮喘病杂志，2010;60(6):1210-1220。https://doi.org/10.1080/02770903.2022.2139718We为这个错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Allergy 医学-过敏

CiteScore

26.10

自引率

9.70%

发文量

393

审稿时长

2 months

期刊介绍： Allergy is an international and multidisciplinary journal that aims to advance, impact, and communicate all aspects of the discipline of Allergy/Immunology. It publishes original articles, reviews, position papers, guidelines, editorials, news and commentaries, letters to the editors, and correspondences. The journal accepts articles based on their scientific merit and quality. Allergy seeks to maintain contact between basic and clinical Allergy/Immunology and encourages contributions from contributors and readers from all countries. In addition to its publication, Allergy also provides abstracting and indexing information. Some of the databases that include Allergy abstracts are Abstracts on Hygiene & Communicable Disease, Academic Search Alumni Edition, AgBiotech News & Information, AGRICOLA Database, Biological Abstracts, PubMed Dietary Supplement Subset, and Global Health, among others.

期刊最新文献

Murine Model of Chronic Spontaneous Urticaria‐Like Skin Single-Cell Omics Analysis of Human Basophils Reveals Two Transcriptionally Distinct Populations. Issue Information Autoclaved Peanuts Exhibit Reduced Immunoglobulin E Binding and Improved Oral Tolerability Polymeric α-Hairpinin Allergens Induce a Functional Response via a Single Antibody.